Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly

Zyprexa sales begin to slide, but Cymbalta aids growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 4Q10

4Q Revenues: $6.2 billion (+4%)

4Q Earnings: $1.2 billion (+28%)

FY Revenues: $23.1 billion (+6%)

FY Earnings: $5.1 billion (+17%)

Comments: Sales growth was driven by Cymbalta, +19% for 4Q10 ($985 million) and +13% for FY10 ($3.5 billion), Alimta (+9% / $569 million in 4Q 10, and +29% / $2.2 billion in FY10), and the Animal Health unit (+20% / $424 million in 4Q10, and +15% / $1.4 billion for FY10), which grew partly because of an acquisition. Zyprexa sales fell 2% in 4Q10 to $1.3 billion, due to lower demand. Effient sales were $47 million in 4Q10, up from $36.3 million in the previous quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters